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ABSTRACT  
Hypertension, specifically pulmonary hypertension, is a syndromethat can affect pediatric patients as well as adults. Pulmonary arterial 
hypertension (PAH) in pediatric patients, while rare, can be a lifethreateningcondition. There is no cure for PAH, only treatment options 
forchildren that are largely based on the results of adult studies. These therapies, however, can improve quality of life and survival. Treatment 
can be challenging because of the less approved medications and tolerable dosage forms for pediatric patients. Pediatric pulmonary arterial 
hypertension (PAH) shares common features of adult disease, but is associated with several additional disorders and challenges that require 
unique approaches. Current classes of medications primarily used to treat pediatric hypertension include phosphodiesterase inhibitors, 
endothelin receptor antagonists, and prostacyclins. Additional agents that may be utilized in selected pediatric patients include calcium channel 
blockers, anticoagulants, and inhalednitric oxide. Updates are provided on issues related to utility of the previous classification system to reflect 
pediatric-specific aetiologies and approaches to medical and interventional management of PAH. Also updates are provided about currently 
available drug substance and their details, pharmaceutical dosage forms and their details along with the mechanism of action,  
pharmacokinetics of the drug. These emerging data are improving the identification of appropriate targets for goal-oriented therapy inchildren. 
Such data will likely improve future advanced pharmaceutical dosage development and product design to enhance outcomes in pediatric PAH. 
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INTRODUCTION 
Pulmonary arterial hypertension is a rare blood vessel 
disorder of the lung in which the pressure in the pulmonary 
artery (the blood vessel that leads from the heart to the 
lungs) rises above normal levels. An increase of the number 
of smooth muscle cells in the walls of small lung arteries (a 
phenomenon called proliferation) that are remodeling the 
vessels, may lead to obstructions in the microcirculation, 
which will then lead to an increase in the blood pressure. 
Chronic thromboembolic pulmonary hypertension is a 
complication representing less than 1% of all cases of acute 
pulmonary embolism (the sudden blocking of a lung artery 
by a clot or foreign material which has been brought to its 
site by the blood current), which directly leads to pulmonary 
hypertension. Pulmonary arterial hypertension and chronic 
thromboembolic pulmonary hypertension are chronically 
debilitating and life-threatening 
Pulmonary arterial hypertension (PAH) is still an important 
cause of morbidity and mortality in children. Despite recent 
developments in PAH-specific therapies, survival of patients 
with idiopathic PAH remains poor and appears to be worse in 
children compared with adults. During the past few years, 
treatment of PAH has undergone a remarkable evolution, 
which has led to the current approval by regulatory agencies 
of few drugs for adult patients from three main 
pharmacological groups (addressing three pathways) and 
four different routes ofadministration (oral, inhaled, 
subcutaneous andintravenous). In pediatric PAH, blood low 
exiting the right side of the heart faces great erresistance due 
to increased muscle present in the walls of the lungs. The 
right ventricle then enlarges and thickens in response, which 
may lead to heart failure. However, emerging therapeutic 
strategies for adult PAH, such as upfront oral combination 
therapy, have not been sufficiently studied in children1. 
Moreover, the complexity of pulmonary hypertensive 
vascular disease (PHVD) in children makes the selection of 
appropriate etherapies a great challenge far away from 
amere prescription of drugs. Therapy of pediatric PH is 
rather characterized by a complex strategy that includes the 
evaluation of severity and prognosis of the individual disease, 
the estimation of efficacy of different drugs, and their 
interaction and combination, as well as supportive and 
generalmeasures1-2. 
Recently, additional surgical and interventional techniques 
for palliation of children with severe PAH have been 
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reported. The beneficial effects ofthese strategies are mainly 
based on the relief of right ventricle (RV) pressure over load 
with a subsequent reduction of the interventricular septum 
shift to the left ventricle (LV), and improvement of systolic 
and diastolic LV performance. Although there is still a lack of 
data on effectiveness, formulation, pharmacokinetics, optimal 
dosing and treatment strategies, data are emerging that allow 
for the definition of appropriate treatment targets and goal-
oriented therapy in children. Nevertheless, children with PAH 
are currently treated with targeted PAH drugs with benefit. 
Conservative treatments overview for PAH have been 
provided and established in many articles1-14. Here with 
provided an overview of recent updates advance treatments 
and available pharmaceutical dosage forms. 
PHARMACOTHERAPY 
Many medications have been used and studied in the 
treatment of pediatric PAH. However, there are three 
medication classes that have been evaluated more thoroughly 
for their efficacy in pediatric PH treatment: 
phosphodiesterasetype 5 (PDE5) inhibitors, endothelin (ET) 
receptor antagonists, and prostacyclinagonists. Other 
medications used are calcium channel blockers, 
anticoagulants, and inhaled nitric oxide (iNO). Prior to 
initiation of targeted PH therapy, thepatient should be 
assessed for acute vasodilator responsiveness via cardiac 
catheterization; left-sided heart disease or pulmonary venous 
disease resultingin an anatomic obstruction should be 
excluded. Medication therapy is determined based on patient 
responsiveness to acute vasodilator testing (AVT; Figure 1)1. 
Acute vasodilator testing is used to assess the response of the 
pulmonary vascular bed to pulmonary-specific vasodilators. 
In children with IPAH or isolated pulmonary hypertensive 
vascular disease, response to AVT is defined as a decrease in 
mPAP of at least 10 mmHg to <40 mmHg, with normal or 
increased cardiacoutput and a decrease in mPAP 20%; an 
increase or no change in cardiacindex; and a decrease or no 
change in pulmonary vascular resistance/systemicvascular 
resistance ratio1-2. 
 
Figure 1- PAH: Pulmonary arterial hypertension; PDE5: 
Phosphdiesterase type 5; ERA: Endothelin receptor 
antagonist. 
Conservative Treatment: 
Therapies typically used for left heart failure have been 
alsoused for the treatment of patients with RV failure. 
Supportivetherapy may include oxygen, anticoagulants, 
diuretics, mineral corticoid receptor antagonists 
(spironolactone), digoxin. These measures are applied on an 
individual basis since the currently available studies provide 
either none or rather ambiguous/contradictory than valid 
data on most of these therapies in (adults and) children with 
PH1-12. 
CHEMISTRY OF PEDIATRIC PULMONARY ARTERIAL 
HYPERTENSION (PAH) DRUG 
Endothelin-1 receptor antagonists 
Bosentan:  
It belongs to a class of highly substituted pyrimidine 
derivatives, with no chiral centers. It is designated chemically 
as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-
phenoxy)-[2,2´]-bipyrimidin4-yl]-
benzenesulfonamidemonohydrate and has the following 
structural formula: 
 
Figure 2 - Bosentan 
Bosentan has a molecular weight of 569.64 and a molecular 
formula of C27H29N5O6S•H2O. Bosentan is a white to yellowish 
powder. It is poorly soluble in water (1.0 mg/100 mL) and in 
aqueous solutions at low pH (0.1 mg/100 mL at pH 1.1 and 
4.0; 0.2 mg/100 mL at pH 5.0). Solubility increases at higher 
pH values (43 mg/100 mL at pH 7.5). In the solid state, 
bosentan is very stable, is not hygroscopic and is not light 
sensitive15. 
Ambrisentan: 
It is selective for the endothelin type-A (ETA) receptor. The 
chemical name of ambrisentan is (+)-(2S)-2-[(4,6-
dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-
diphenylpropanoic acid. It has a molecular formula of 
C22H22N2O4 and a molecular weight of 378.42. It contains a 
single chiral center determined to be the (S) configuration 
and has the following structural formula: 
 
Figure 3 - Ambrisentan 
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Ambrisentan is a white to off-white, crystalline solid. It is a 
carboxylic acid with a pKa of 4.0. Ambrisentan is practically 
insoluble in water and in aqueous solutions at low pH. 
Solubility increases in aqueous solutions at higher pH. In the 
solid state ambrisentan is very stable, is not hygroscopic, and 
is not light sensitive16. 
Macitentan:  
The chemical name of macitentan is N-[5-(4-Bromophenyl)-
6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-
N'propylsulfamide. It has a molecular formula of 
C19H20Br2N6O4S and a molecular weight of 588.27. 
Macitentan is achiral and has the following structural 
formula: 
 
Figure 4 - Macitentan 
Macitentan is a crystalline powder that is insoluble in water. 
In the solid state macitentan is very stable, is not hygroscopic, 
and is not light sensitive17. 
Phosphodiesterase Inhibitors (PDE-5i) 
Sildenafil : 
It is the citrate salt of sildenafil, a selective inhibitor of cyclic 
guanosine monophosphate(cGMP)-specific phosphor-
diesterase type-5 (PDE-5).  Sildenafil citrate is designated 
chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-
1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] 
sulfonyl]-4-methylpiperazine citrate and has the following 
structural formula: 
 
Figure 5 - Sildenafil citrate 
Sildenafil citrate is a white to off-white crystalline powder 
with a solubility of 3.5 mg/mL in water. Sildenafil citrate has 
the empirical formula C28H38N6O11S representing a molecular 
weight of 666.718. 
Tadalafil :  
It is an oral treatment for pulmonary arterial hypertension, is 
a selective inhibitor of cyclic guanosine monophosphate 
(cGMP)–specific phosphodiesterase type 5 (PDE5). Tadalafil 
has the empirical formula C22H19N3O4 representing a 
molecular weight of 389.41. The structural formula is: 
 
Figure 6 – Tadalafil 
The chemical designation is pyrazino[1´,2´:1,6]pyrido[3,4–
b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)2,3,6,7,12,12a-
hexahydro-2-methyl-, (6R,12aR)-. It is a crystalline solid that 
is practically insoluble in water and very slightly soluble in 
ethanol19. 
Guanylate cyclase stimulators 
Riociguat : 
Riociguat is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-lH-
pyrazolo[3,4-b]pyridin-3-yl]-5-
pyrimidinyl(methyl)carbamate with the following structural 
formula: 
 
Figure 7 - Riociguat 
Riociguat is a white to yellowish, crystalline, non-hygroscopic 
substance with a molecular weight of 422.42 g/mol. It has the 
empirical formula of C20H19FN8O2. In solid form it is stable to 
temperature, light, and humidity20.  
The solubility at 25°C in water: 4 mg/L, in ethanol: 800 mg/L, 
in 0.1 HCl (pH 1): 250 mg/L and in buffer (phosphate) pH.7: 3 
mg/L. In the pH range of 2 to 4 the solubility showed strong 
pH-dependency. Solubility increases at lower pH values20. 
Vericiguat : 
Vericiguat is Methyl (4,6-diamino-2-(5-fluoro-1-(2-
fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-
yl)carbamate with the following structural formula: 
 
Figure 8 - Vericiguat 
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It has the empirical formula of C19H16F2N8O2with a molecular 
weight of 426.388 g/mol.  In solid form it is stable to 
temperature, light, and humidity21,22. 
Prostacyclin Analogues (Pca; Prostaglandin I Receptor 
Agonists; Ip Receptor Agonists) 
Epoprostenol : 
Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of 
arachidonic acid, is a naturally occurring prostaglandin with 
potent vasodilatory activity and inhibitory activity of platelet 
aggregation. 
Epoprostenol is (5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-
dihydroxyprosta-5,13-dien-1-oic acid. Epoprostenol sodium 
has a molecular weight of 374.45 and a molecular formula of 
C20H31NaO5. The structural formula is: 
 
Figure 9 - Epoprostenol 
Epoprostenol is a white to off-white lyophilized powder 
material. It is reconstituted with Sterile Water for Injection, 
USP, or Sodium Chloride 0.9% Injection, USP. The 
reconstituted solution of Epoprostenol has a pH ranging from 
11 to 13 and is increasingly unstable at a lower pH23. 
Trepostinil : 
Treprostinil is (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-
hydroxy-1-[(3S)-3-hydroxyoctyl]1H-benz[f]inden-5-
yl]oxy]acetic acid. Treprostinil has a molecular weight of 
390.52 and a molecular formula of C23H34O5. The structural 
formula of treprostinil is: 
 
Figure 10 - Treprostinil 
Treprostinil is chemically stable at room temperature and 
neutral pH. Sterile Diluent for Remodulin is a high-pH 
(pH~10.4) glycine diluent supplied in a 50 mL vial containing 
50 mL of Sterile Diluent for Remodulin. Each vial contains 94 
mg glycine, 73.3 mg sodium chloride, sodium hydroxide (to 
adjust pH), and water for injection24. 
Iloprost : 
The chemical name for iloprost is (E)-(3aS,4R,5R,6aS)-
hexahydro-5-hydroxy-4-[(E)-(3S,4RS)-3- hydroxy-4-methyl-
1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acid. Iloprost 
consists of a mixture of the 4R and 4S diastereomers at a 
ratio of approximately 53:47. The molecular formula of 
iloprost is C22H32O4. Its relative molecular weight is 360.49. 
The structural formula is shown below: 
 
Figure 11 - Iloprost 
Iloprost is an oily substance, which is soluble in methanol, 
ethanol, ethyl acetate, acetone and pH 7 buffer, sparingly 
soluble in buffer pH 9, and very slightly soluble in distilled 
water, buffer pH 3, and buffer pH 525. 
Beraprost : 
Beraprost is  sodium 4-{(1R,2R,3aS,8bS)-2-Hydroxy-1-
[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2,3,3a,8b-
tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic 
acid.  
The Structural formula of beraprostis: 
 
Figure 12 – Beraprost 
Beraprost has a molecular weight of 398.492 and a molecular 
formula of C24H30O5. It is chemically stable at room 
temperature and neutral pH26,27. 
Selexipag : 
UPTRAVI (selexipag) is a selective non-prostanoid IP 
prostacyclin receptor agonist. The chemical name of 
selexipag is 2-{4-[(5,6-diphenylpyrazin-2-
yl)(isopropyl)amino]butoxy}-N(methylsulfonyl) acetamide. It 
has a molecular formula of C26H32N4O4S and a molecular 
weight of 496.62. Selexipag has the following structural 
formula: 
 
Figure 13 -Selexipag 
Selexipag is a pale yellow crystalline powder that is 
practically insoluble in water. In the solid state selexipag is 
very stable, is not hygroscopic, and is not light sensitive28. 
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TREATMENT ALGORITHM FOR PEDIATRIC PULMONARY ARTERIAL HYPERTENSION (PAH) 
 
Figure 14 -Treatment algorithm for pediatric pulmonary arterial hypertension (PAH)2.  
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DOSAGE FORM AND MECHANISAM OF PEDIATRIC PULMONARY ARTERIAL HYPERTENSION (PAH) DRUG: 
Table 1 - Endothelin-1 receptor antagonists 
Drug 
Name 
Brand name Dosage 
form 
Excipients used Mechanism of action 
Endothelin-1 receptor antagonists 
Bosentan15 TRACLEER® 
(bosentan) 
tablets 
Immediate 
release 
tablets 
Bosentan is available as 62.5 mg 
and 125 mg film-coated tablets for 
oral administration, and contains 
the following excipients: corn 
starch, pregelatinized starch, 
sodium starch glycolate, povidone, 
glyceryl behenate, magnesium 
stearate, 
hydroxypropylmethylcellulose, 
triacetin, talc, titanium dioxide, iron 
oxide yellow, iron oxide red, and 
ethylcellulose. Each Tracleer 62.5 
mg tablet contains 64.54 mg of 
bosentan monohydrate, equivalent 
to 62.5 mg of anhydrous bosentan. 
Each Tracleer 125 mg tablet 
contains 129.08 mg of bosentan 
monohydrate, equivalent to 125 mg 
of anhydrous bosentan. 
Bosentan is a specific and competitive 
antagonist at endothelin receptor types 
ETA and ETB. Bosentan has a slightly 
higher affinity for ETA receptors than for 
ETB receptors. The clinical impact of dual 
endothelin blockage isunknown. 
Endothelin-1 (ET-1) is a neurohormone, 
the effects of which are mediated by 
binding to ETA and ETB receptors in the 
endothelium and vascular smooth muscle. 
ET-1 concentrations are elevated in plasma 
and lung tissue of patients with PAH, 
suggesting a pathogenic role for ET-1 in 
this disease. 
TRACLEER® 
(bosentan) 
tablets for 
oral 
suspension 
Tablets for 
suspension 
Bosentan is also available as a 32 
mg tablet for oral suspension and 
contains the following excipients: 
cellulose microcrystalline, calcium 
hydrogen phosphate anhydrous, 
croscarmellose sodium, silica 
colloidal anhydrous, tartaric acid, 
tuttifrutti flavor, aspartame (E951), 
acesulfame potassium, and 
magnesium stearate. Each 
dispersible tablet contains 1.87 mg 
of phenylalanine. Each dispersible 
tablet contains 33.045 mg of 
bosentan monohydrate, equivalent 
to 32 mg anhydrous bosentan. 
Ambrisent
an16 
Letairis 
(ambrisentan
) tablets 
Immediate 
release 
tablets 
Ambrisentan is available as 5 mg 
and 10 mg film-coated tablets for 
once daily oral administration. The 
tablets include the following 
inactive ingredients: 
croscarmellose sodium, lactose 
monohydrate, magnesium stearate 
and microcrystalline cellulose. The 
tablets are film-coated with a 
coating material containing FD&C 
Red #40 aluminum lake, lecithin, 
polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide. 
Each square, pale pink Letairis 
tablet contains 5 mg of 
ambrisentan. Each oval, 
deep pink Letairis tablet contains 
10 mg of ambrisentan. 
Endothelin-1 (ET-1) is a potent autocrine 
and paracrine peptide. Two receptor 
subtypes, ETA and ETB, mediate the effects 
of ET-1 in the vascular smooth muscle and 
endothelium. The primary actions of ETA 
are vasoconstriction and cell proliferation, 
while the predominant actions of ETB 
arevasodilation, antiproliferation, and ET-1 
clearance. In patients with PAH, plasma ET-
1 concentrations are increased as much as 
10-fold and correlate. with increased mean 
right atrial pressure and disease severity. 
ET-1 and ET-1 mRNA concentrations are 
increased as much as 9-fold in the lung 
tissue of patients with PAH, primarily in the 
endothelium of pulmonary arteries. These 
findings suggest that ET-1 may play a 
critical role in the pathogenesis and 
progression of PAH. Ambrisentan is a high-
affinity (Ki=0.011 nM) ETA receptor 
antagonist with a high selectivity for the 
ETA versus ETB receptor (>4000-fold). The 
clinical impact of high selectivity for ETA is 
not known. 
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Macitentan
17 
OPSUMIT 
(macitentan) 
tablets 
Immediate 
release 
tablets 
OPSUMIT is available as a 10 mg 
film-coated tablet for once daily 
oral administration. The tablets 
include the following inactive 
ingredients: lactose monohydrate, 
magnesium stearate, micro-
crystalline cellulose, polysorbate 
80, povidone, and sodium starch 
glycolate Type A. The tablets are 
film-coated with a coating material 
containing polyvinyl alcohol, soya 
lecithin, talc, titanium dioxide, and 
xanthan gum. 
Endothelin (ET)-1 and its receptors (ETA 
and ETB) mediate a variety of deleterious 
effects, such as vasoconstriction, fibrosis, 
proliferation, hypertrophy, and 
inflammation. In disease conditions such as 
PAH, the local ET system is upregulated 
and is involved in vascular hypertrophy 
and in organ damage. Macitentan is an 
endothelin receptor antagonist that 
prevents the binding of ET-1 to both ETA 
and ETB receptors. Macitentan displays 
high affinity and sustained occupancy of 
the ET receptors in human pulmonary 
arterial smooth muscle cells. One of the 
metabolites of macitentan is also 
pharmacologically active at the ET 
receptors and is estimated to be about 20% 
as potent as the parent drug in vitro. 
 
Table 2 - Phosphodiesterase inhibitors (PDE-5i) 
Drug Name Brand name Dosage form Excipients used Mechanism of action 
 
Phosphodiesterase inhibitors (PDE-5i) 
Sildenafil18 REVATIO 
(sildenafil) 
tablets 
Immediate 
release tablets 
REVATIO is formulated as white, 
film-coated round tablets with 20 
mg of sildenafil for oral 
administration. In addition to the 
active ingredient, sildenafil 
citrate, each tablet contains the 
following inactive ingredients: 
microcrystalline cellulose, 
anhydrous dibasic calcium 
phosphate, croscarmellose 
sodium, magnesium stearate, 
hypromellose, titanium dioxide, 
lactose monohydrate, and 
triacetin. 
Sildenafil is an inhibitor of cGMP 
specific phosphodiesterase type-5 
(PDE-5) in the smooth muscle of 
the pulmonary vasculature, where 
PDE-5 is responsible for 
degradation of cGMP. Sildenafil, 
therefore, increases cGMP within 
pulmonary vascular smooth muscle 
cells resulting in relaxation. In 
patients with PAH, this can lead to 
vasodilation of the pulmonary 
vascular bed and, to a lesser 
degree, vasodilatation in the 
systemic circulation. 
Studies in vitro have shown that 
sildenafil is selective for PDE-5. Its 
effect is more potent on PDE-5 than 
on other known 
phosphodiesterases (10-fold for 
PDE6, greater than 80-fold for 
PDE1, greater than 700-fold for 
PDE2, PDE3, PDE4, PDE7, PDE8, 
PDE9, PDE10, and PDE11). The 
approximately 4,000-fold 
selectivity for PDE-5 versus PDE3 
is important because PDE3 is 
involved in control of cardiac 
contractility. Sildenafil is only 
about 10-fold as potent for PDE-5 
compared to PDE6, an enzyme 
found in the retina and involved in 
the photo transduction pathway of 
the retina. This lower selectivity is 
thought to be the basis for 
abnormalities related to color 
vision observed with higher doses 
or plasma levels. 
In addition to pulmonary vascular 
smooth muscle and the corpus 
cavernosum, PDE-5 is also found in 
other tissues including vascular 
and visceral smooth muscle and in 
REVATIO 
(sildenafil) for 
oral suspension 
Powder for 
oral 
suspension 
REVATIO is supplied in an amber 
glass bottle as a white to off-
white powder providing a white 
to off-white grape flavored oral 
suspension when constituted. 
Bottles containing 32.27 g 
powder for oral suspension are 
intended for constitution with 90 
mL water to produce an oral 
suspension containing 10 mg/mL 
sildenafil. In addition to the 
bottle, a press-in bottle adapter 
and an oral dosing syringe (2 mL) 
are provided. The inactive 
ingredients include sorbitol, 
citric acid anhydrous, sucralose, 
sodium citrate dihydrate, 
xanthan gum, titanium dioxide, 
sodium benzoate, colloidal silicon 
dioxide anhydrous and grape 
flavor 
REVATIO 
(sildenafil) 
injection 
Intravenous 
injection 
REVATIO is supplied as a clear, 
colorless, sterile, ready to use 
solution containing 10 mg (12.5 
mL) of sildenafil. Each mL of 
solution contains 1.124 mg 
sildenafil citrate, 50.5 mg 
Dubey et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2020; 10(2-s):156-170 
ISSN: 2250-1177                                                                                  [163]                                                                                 CODEN (USA): JDDTAO 
dextrose and water for injection. platelets. The inhibition of PDE-5 in 
these tissues by sildenafil may be 
the basis for the enhanced platelet 
anti-aggregatory activity of nitric 
oxide observed in vitro, and the 
mild peripheral arterial-venous 
dilatation in vivo. 
Tadalafil19 ADCIRCA 
(tadalafil) 
tablets 
Immediate 
release tablets 
ADCIRCA is available as orange, 
film–coated, almond–shaped 
tablets for oral administration. 
Each tablet contains 20 mg of 
tadalafil and the following 
inactive ingredients: 
croscarmellose sodium, 
hydroxypropyl cellulose, 
hypromellose, iron oxide, lactose 
monohydrate, magnesium 
stearate, microcrystalline 
cellulose, sodium lauryl sulfate, 
talc, titanium dioxide, and 
triacetin. 
Tadalafil is an inhibitor of 
phosphodiesterase type 5 (PDE5), 
the enzyme responsible for the 
degradation of cyclic guanosine 
monophosphate (cGMP). 
Pulmonary arterial hypertension is 
associated with impaired release of 
nitric oxide by the vascular 
endothelium and consequent 
reduction of cGMP concentrations 
in the pulmonary vascular s mooth 
muscle. PDE5 is the predominant 
phosphodiesterase in the 
pulmonary vasculature. Inhibition 
of PDE5 by tadalafil increases the 
concentrations of cGMP resulting in 
relaxation of pulmonary vascular 
smooth muscle cells and 
vasodilation of the pulmonary 
vascular bed. 
Studies in vitro have demonstrated 
that tadalafil is a selective inhibitor 
of PDE5. PDE5 is found in 
pulmonary vascular smooth 
muscle, visceral smooth muscle, 
corpus cavernosum, skeletal 
muscle, platelets, kidney, lung, 
cerebellum, and pancreas. 
 
Table 3 - Guanylate cyclase stimulators 
Drug 
Name 
Brand name Dosage 
form 
Excipients used Mechanisum of action 
Guanylate cyclase stimulators 
Riociguat20 Adempas 
(riociguat) 
tablets 
Immediate 
release 
tablets 
The inactive ingredients 
are cellulose 
microcrystalline, 
crospovidone, 
hypromellose 5cP, lactose 
monohydrate, magnesium 
stearate, sodium 
laurylsulfate, 
hydroxypropylcellulose, 
hypromellose 3cP, 
propylene glycol, titanium 
dioxide. 
Riociguat is a stimulator of soluble guanylate cyclase 
(sGC), an enzyme in the cardiopulmonary system and 
the receptor for nitricoxide (NO). 
When NO binds to sGC, the enzyme catalyzes synthesis 
of the signaling molecule cyclic guanosine 
monophosphate (cGMP). Intracellular cGMP plays an 
important role in regulating processes that influence 
vascular tone, proliferation, fibrosis andinflammation. 
PAH is associated with endothelial dysfunction, 
impaired synthesis of nitric oxide and insufficient 
stimulation of the NO-sGC-cGMP pathway. Riociguat 
has a dual mode of action. It sensitizes sGC to 
endogenous NO by stabilizing the NO-sGC binding. 
Riociguat also directly stimulates sGC via a different 
binding site, independently of NO.Riociguat stimulates 
the NO-sGC-cGMP pathway and leads to increased 
generation of cGMP with subsequent vasodilation.The 
active metabolite (M1) of riociguat is 1/3 to 1/10 as 
potent as riociguat. 
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Table 4 - Prostacyclin analogues (PCA; prostaglandin I receptor agonists; IP receptor agonists) 
Drug Name Brand name Dosage form Excipients used Mechanism of action 
 
Prostacyclin analogues (PCA; prostaglandin I receptor agonists; IP receptor agonists) 
Epoprostenol23 VELETRI 
(epoprostenol) 
for Injection 
Infusion, 
intravenous 
infusion 
Epoprostenol sodium is the 
sodium salt of epoprostenol, 
formulated as a sterile 
lyophilized powder for 
intravenous (IV) 
administration. Each vial of 
VELETRI contains 
epoprostenol sodium 
equivalent to either 0.5 mg 
(500,000 ng) or 1.5 mg 
(1,500,000 ng) epoprostenol, 
100 mg sucrose, and 50 mg 
arginine. Sodium hydroxide is 
added to adjust pH. 
Epoprostenol has 2 major 
pharmacological actions: (1) 
direct vasodilation of pulmonary 
and systemic arterial vascular 
beds, and (2) inhibition of platelet 
aggregation. 
Trepostinil24 REMODULIN® 
(treprostinil) 
Injection 
Injection, for 
subcutaneous 
or intravenous 
Sterile Diluent for Remodulin 
is a high-pH (pH~10.4) glycine 
diluent supplied in a 50 mL 
vial containing 50 mL of 
Sterile Diluent for Remodulin. 
Each vial contains 94 mg 
glycine, 73.3 mg sodium 
chloride, sodium hydroxide (to 
adjust pH), and water for 
injection 
The major pharmacologic actions 
of treprostinil are direct 
vasodilation of pulmonary and 
systemic arterial vascular beds, 
and inhibition of platelet 
aggregation. 
Iloprost25 Ventavis 
(iloprost) Solution 
Inhalation 
Solution 
Each mL of the aqueous 
solution 
contains 0.01 mg iloprost, 0.81 
mg ethanol, 0.121 mg 
tromethamine, 9.0 mg sodium 
chloride, and 
approximately 0.51 mg 
hydrochloric acid (for pH 
adjustment to 8.1) in water for 
injection. The 
solution contains no 
preservatives. 
Iloprost is a synthetic analog of 
prostacyclin PGI2. Iloprost dilates 
systemic and pulmonary 
arterial vascular beds. It also 
affects platelet aggregation but 
the relevance of this effect to the 
treatment of pulmonary 
hypertension is unknown. The 
two diastereoisomers of iloprost 
differ in their potency 
in dilating blood vessels, with the 
4S isomer substantially more 
potent than the 4R isomer. 
Selexipag28 UPTRAVI® 
(selexipag) 
tablets. 
Immediate 
release tablets 
The tablets include the 
following inactive 
ingredients:D-mannitol, corn 
starch, low substituted HPC, 
HPMC, and magnesium 
stearate. The tablets are film 
coated with a coating material 
containing hypromellose, 
propylene glycol, titanium 
dioxide, carnauba wax along 
with mixtures of iron oxide 
red, iron oxide yellow or iron 
oxide black. 
Selexipag is an oral prostacyclin 
receptor (IP receptor) agonist 
that is structurally distinct from 
prostacyclin. Selexipag is 
hydrolyzed by carboxylesterase 1 
to yield its active metabolite, 
which is approximately 37-fold as 
potent as selexipag. Selexipag and 
the active metabolite are selective 
for the IP receptor versus other 
prostanoid receptors (EP1-4, DP, 
FP, and TP). 
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PHARMACOKINETICS OF PEDIATRIC PULMONARY ARTERIAL HYPERTENSION (PAH) DRUG: 
Table 5 – ADME of Bosentan 
Drug Name Absorption Distribution Metabolism Elimination 
Bosentan15 The absolute 
bioavailability of 
bosentan in normal 
volunteers is about 
50% and is 
unaffected by food.  
After oral administration, 
maximum plasma 
concentrations of bosentan 
are attained within 3–5 hours 
and the terminal elimination 
half-life is about 5 hours in 
healthy adult subjects. The 
exposure to bosentan after 
intravenous and oral 
administration is about twice 
as high in adult patients with 
PAH as it is in healthy adult 
subjects. 
 
Bosentan has three 
metabolites, one of 
which is 
pharmacologically active 
and may contribute 
10%–20% of the effect 
of bosentan. Bosentan is 
an inducer of CYP2C9 
and CYP3A and possibly 
also of CYP2C19. 
Bosentan is eliminated by 
biliary excretion following 
metabolism in the liver. 
Less than 3% of an 
administered oral dose is 
recovered in urine. Total 
clearance after a single 
intravenous dose is about 
4 L/h in patients with 
PAH. 
 
Table 6 – ADME of Ambrisentan 
Drug Name Absorption Distribution Metabolism Elimination 
Ambrisentan29 Ambrisentan was 
well absorbed 
following oral 
administration. It 
also showed high 
absolute oral 
bioavailability in 
preclinical 
species, 
indicating that it 
undergoes little 
or no first pass 
metabolism. 
In vitro results showed 
that ambrisentan binds 
to plasma proteins to a 
higher extent in 
humans (98.9%) than 
in preclinical species 
(91.8-97.2%). In human 
serum, it was apparent 
that albumin was the 
primary binding 
protein in human 
plasma. The results of a 
rat tissue distribution 
study with [14C]-
ambrisentan indicated 
a wide distribution of 
drug into tissues but 
elimination occurred 
relatively rapidly. 
Metabolism data obtained 
following administration of 
[14C]-ambrisentan showed that 
metabolic 
pathways for ambrisentan were 
qualitatively similar in various 
species. The metabolites 
identified 
include 4,6 dimethyl-2-
hydroxypryimidine, ambrisentan 
glucuronide, 
hydroxylatedambrisentan, O-
demethylatedambrisentan, 
dihydroxylatedambrisentan, 
dihydroxylatedambrisentan 
glucuronide, hydroxylated 
ambrisentan glucuronide, and 
Odemethylhydroxymethyl 
ambrisentan.  
Based on disposition 
studies conducted with 
[14C]-ambrisentan, it 
was apparent that the 
primary route of 
excretion of drug-
related material was 
faeces in all preclinical 
species as well as in 
humans. In 12/44 
humans, about 66% of 
the dose was 
recovered in faeces 
and in animal species, 
the faecal recovery 
generally accounted 
for 69%-91% of the 
dose. Urinary 
excretion was a minor 
route of elimination in 
both animal species (7-
23%) as well as in 
humans (23%). 
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Table 7 – ADME of Macitentan 
Drug Name Absorption Distribution Metabolism Elimination 
Macitentan30 The absolute 
bioavailability of 
macitentan could 
not be established, 
as the development 
of an i.v. formulation 
was not technically 
feasible. Maximum 
plasma 
concentrations of 
macitentan are 
achieved about 8 
hours after 
administration.  
Macitentan and ACT-
132577 are well distributed 
into tissues as indicated by 
an apparent volume of 
distribution (Vss/F) of 
approximately 50L and 40L 
for macitentan and ACT-
132577, respectively. 
Macitentan and its active 
metabolite are highly bound 
to plasma proteins (>99%), 
primarily to albumin. 
Macitentan undergoes 
biotransformation by 
hydroxylation, with 
CYP3A4 isoenzyme as 
the major contributor. 
The main metabolite is 
ACT-132577 (active 
M6), present at 
approximately 71% of 
total drug exposure in 
plasma. No particularly 
relevant consequences 
of polymorphism in 
CYP3A4 are expected. 
The major excretion route 
of macitentan in humans, 
in the form of metabolites, 
is via urine, accounting for 
about 50% of the dose, 
while approximately 24% 
of the administered dose 
was recovered in faeces. 
Neither unchanged 
macitentan nor the active 
metabolite ACT-132577 
were recovered in urine. 
 
Table 8 – ADME of Sildenafil 
Drug Name Absorption Distribution  Metabolism Elimination 
Sildenafil18 REVATIO is rapidly 
absorbed after oral 
administration, 
with a mean 
absolute 
bioavailability of 
41% (25-63%). 
Maximum 
observed plasma 
concentrations are 
reached within 30 
to 120 minutes 
(median 60 
minutes) of oral 
dosing in the fasted 
state.  
The mean steady state 
volume of distribution 
(Vss) for sildenafil is 
105 L, indicating 
distribution into the 
tissues. Sildenafil and its 
major circulating N-
desmethyl metabolite 
are both approximately 
96% bound to plasma 
proteins. Protein 
binding is independent 
of total drug 
concentrations. 
Bioequivalence was 
established between the 
20 mg tablet and the 10 
mg/mL oral suspension 
when administered as a 
20 mg single oral dose 
of sildenafil (as citrate). 
Sildenafil is cleared 
predominantly by the CYP3A 
(major route) and 
cytochrome P450 2C9 
(CYP2C9, minor route) 
hepatic microsomal 
isoenzymes. The major 
circulating metabolite results 
from N-desmethylation of 
sildenafil, and is, itself, 
further metabolized. This 
metabolite has a 
phosphodiesterase selectivity 
profile similar to sildenafil 
and an in vitro potency for 
PDE-5 approximately 50% of 
the parent drug. In healthy 
volunteers, plasma 
concentrations of this 
metabolite are approximately 
40% of those seen for 
sildenafil, so that the 
metabolite accounts for 
about 20% of sildenafil’s 
pharmacologic effects. 
After either oral or 
intravenous 
administration, sildenafil is 
excreted as metabolites 
predominantly in the feces 
(approximately 80% of the 
administered oral dose) 
and to a lesser extent in 
the urine (approximately 
13% of the administered 
oral dose). 
REVATIO Injection: The 
pharmacokinetic profile of 
REVATIO has been 
characterized following 
intravenous 
administration. A 10 mg 
dose of REVATIO Injection 
is predicted to provide a 
pharmacological effect of 
sildenafil and its N-
desmethyl metabolite 
equivalent to that of a 20 
mg oral dose. 
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Table 9 – ADME of Tadalafil 
Drug Name Absorption Distribution  Metabolism Elimination 
Tadalafil19 After single oral-dose 
administration, the 
maximum observed 
plasma concentration 
(Cmax) of tadalafil is 
achieved between 2 
and 8 hours (median 
time of 4 hours). 
Absolute bioavailability 
of tadalafil following 
oral dosing has not 
been determined. 
The mean apparent 
volume of distribution 
following oral 
administration is 
approximately 77 L, 
indicating that tadalafil 
is distributed into 
tissues. At therapeutic 
concentrations, 94% of 
tadalafil in plasma is 
bound to proteins. 
Tadalafil is predominantly 
metabolized by CYP3A to a 
catechol metabolite. The 
catechol metabolite 
undergoes extensive 
methylation and 
glucuronidation to form 
the methylcatechol and 
methylcatechol 
glucuronide conjugate, 
respectively. The major 
circulating metabolite is 
the methylcatechol 
glucuronide. 
Following 40 mg, the 
mean oral clearance for 
tadalafil is 3.4 L/hr and 
the mean terminal half-
life is 15 hours in healthy 
subjects. In patients with 
pulmonary hypertension 
not receiving 
concomitant bosentan, 
the mean oral clearance 
for tadalafil is 1.6 L/hr, 
and the mean terminal 
half-life is 35 hours. . 
 
Table 10 – ADME of Riociguat 
Drug Name Absorption Distribution  Metabolism Elimination 
Riociguat20 The absolute 
bioavailability of 
riociguat is about 
94%. Peak plasma 
riociguat 
concentrations 
were observed 
within 1.5 hours 
after tablet intake. 
Food does not 
affect the 
bioavailability of 
riociguat.  
The volume of 
distribution at steady 
state is approximately 
30 L. Plasma protein 
binding in humans is 
approximately 95%, 
with serum albumin and 
α1–acidic glycoprotein 
being the main binding 
components. Riociguat 
is a substrate of P-gp 
and BCRP. 
Riociguat is mainly cleared 
by metabolism by CYP1A1, 
CYP3A, CYP2C8 and CYP2J2. 
Formation of the major active 
metabolite, M1, is catalyzed 
by CYP1A1, which is 
inducible by polycyclic 
aromatic hydrocarbons such 
as those present in cigarette 
smoke. M1 is further 
metabolized to the inactive 
N-glucuronide. Plasma 
concentrations of M1 in 
patients with PAH are about 
half those for riociguat 
Following oral 
administration of 
radiolabeled riociguat in 
healthy individuals, about 
40 and 53% of the total 
radioactivity was 
recovered in urine and 
feces, respectively. There 
appears to be considerable 
variability in the 
proportion of metabolites 
and unchanged riociguat 
excreted, but metabolites 
were the major 
components of the dose 
excreted in most 
individuals. 
 
 
Table 11 – ADME of Epoprostenol 
Drug Name Absorption Distribution  Metabolism Elimination 
Epoprostenol23 The in vitro half-
life of 
epoprostenol in 
human blood at 
37°C and pH 7.4 is 
approximately 6 
minutes; 
therefore, the in 
vivo half-life of 
epoprostenol in 
humans is 
expected to be no 
greater than 6 
minutes. 
Animal studies using 
tritium-labeled 
epoprostenol have 
indicated a high 
clearance (93 
mL/kg/min), small 
volume of distribution 
(357 mL/kg), and a 
short half-life (2.7 
minutes). During 
infusions in animals, 
steady-state plasma 
concentrations of 
tritium-labeled 
epoprostenol were 
reached within 15 
minutes and were 
proportional to 
infusion rates. 
Tritium-labeled 
epoprostenol has been 
administered to humans in 
order to identify the 
metabolic products of 
epoprostenol. Epoprostenol 
is metabolized to 2 primary 
metabolites: 6keto-PGF1α 
(formed by spontaneous 
degradation) and 6,15-
diketo-13,14-dihydro-PGF1α 
(enzymatically formed), 
both of which have 
pharmacological activity 
orders of magnitude less 
than epoprostenol in animal 
test systems 
The recovery of 
radioactivity in urine and 
feces over a 1-week 
period was 82% and 4% 
of the administered dose, 
respectively. Fourteen 
additional minor 
metabolites have been 
isolated from urine, 
indicating that 
epoprostenol is 
extensively metabolized 
in humans. 
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Table 12 – ADME of Trepostinil 
Drug Name Absorption Distribution  Metabolism Elimination 
Trepostinil24 Trepostinil is 
relatively rapidly and 
completely absorbed 
after subcutaneous 
infusion, with an 
absolute 
bioavailability 
approximating 
100%. Steady-state 
concentrations 
occurred in 
approximately 10 
hours. 
Concentrations in 
patients treated with 
an average dose of 
9.3 ng/kg/min were 
approximately 2,000 
ng/L. 
The volume of 
distribution of the 
drug in the central 
compartment is 
approximately 14 
L/70 kg ideal body 
weight. Remodulin at 
in vitro 
concentrations well 
above what is 
clinically relevant 
was 91% bound to 
human plasma 
protein. 
Treprostinil is substantially 
metabolized by the liver, 
primarily by CYP2C8. In a study 
conducted in healthy 
volunteers using [14C] 
treprostinil, 79% and 13% of 
the subcutaneous dose was 
recovered in the urine and 
feces, respectively, over 10 
days. Only 4% was excreted as 
unchanged treprostinil in the 
urine. Five metabolites were 
detected in the urine, ranging 
from 10% to 16% and 
representing 64% of the dose 
administered. 
The elimination of 
treprostinil (following 
subcutaneous 
administration) is biphasic, 
with a terminal elimination 
half-life of approximately 4 
hours using a two-
compartment model. 
Systemic clearance is 
approximately 30 L/hour 
for a 70 kg person. 
 
Table 13 – ADME of Iloprost 
Drug Name Absorption Distribution  Metabolism Elimination 
Iloprost25 The absolute 
bioavailability of 
inhaled iloprost has 
not been determined. 
Following 
intravenous infusion, 
the apparent steady-
state volume of 
distribution was 0.7 
to 0.8 L/kg in healthy 
subjects. Iloprost is 
approximately 60% 
protein-bound, 
mainly to albumin, 
and this ratio is 
concentration-
independent in the 
range of 30 to 3000 
pg/mL. 
Clearance in normal subjects 
was approximately 20 
mL/min/kg. Iloprost is 
metabolized principally via ß-
oxidation of the carboxyl side 
chain. The main metabolite is 
tetranor-iloprost, which is 
found in the urine in free and 
conjugated form. In animal 
experiments, tetranor-
iloprostwas pharmacologically 
inactive. 
A mass-balance study 
using intravenously and 
orally administered [3H]-
iloprost in healthy subjects 
(n=8) showed recovery of 
total radioactivity over 14 
hours post-dose, was 81%, 
with 68% and 12% 
recoveries in urine and 
feces, respectively 
 
Table 14 – ADME of Selexipag 
Drug Name Absorption Distribution  Metabolism Elimination 
Selexipag28 The absolute 
bioavailability of 
selexipag is 
approximately 49%. 
Upon oral 
administration, 
maximum observed 
plasma 
concentrations of 
selexipag and its 
active metabolite are 
reached within about 
1–3 hours and 3–4 
hours, respectively. 
The volume of 
distribution of 
selexipag at steady 
state is 11.7 L. 
Selexipag and its 
active metabolite are 
highly bound to 
plasma proteins 
(approximately 99% 
in total and to the 
same extent to 
albumin and alpha1-
acid glycoprotein). 
Selexipag is hydrolyzed to its 
active metabolite, (free 
carboxylic acid) in the liver and 
intestine by carboxylesterases. 
Oxidative metabolism, 
catalyzed mainly by CYP2C8 
and to a smaller extent by 
CYP3A4, leads to the formation 
of hydroxylated and 
dealkylated products. UGT1A3 
and UGT2B7 are involved in the 
glucuronidation of the active 
metabolite. Except for the 
active metabolite, none of the 
circulating metabolites in 
human plasma exceeds 3% of 
the total drug-related material. 
Elimination of selexipag is 
predominately via 
metabolism with a mean 
terminal half-life of 0.8-2.5 
hours. The terminal half-
life of the active metabolite 
is 6.2-13.5 hours. There is 
minimal accumulation of 
the active metabolite upon 
twice daily repeat 
administration suggesting 
that the effective half-life is 
in the range of 3-4 hours.  
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CONCLUSION: 
This systematic review accomplishes 3 important objectives:  
(a) This underlines the need for effective therapies to treat 
the broad range of PH presentations in neonataland pediatric 
pulmonology, cardiology, and critical care. 
(b) This intensely suggests that PDE5 inhibitors improve 
oxygenation and hemodynamic parameters in pediatric 
patients. 
(c) This repeats the need for additional well-planned, 
prospective, comparative studies of the safety and efficacy of 
PDE inhibitors, other pulmonary vasodilators, and placebo 
controls in infants and children with PH53. 
In the relatively small number of children studied, the 
survival rate was better in those children given combination 
therapy with epoprostenol and bosentan, with or without 
sildenafil, than in those on monotherapy. The indication for 
additional therapy was either an unsatisfactory response to 
initial therapy (epoprostenol or bosentan) or clinical 
deterioration. The concept of starting treatment with a single 
agent, preferably an oral drug, followed by the addition of a 
different agent(s) if necessary is supported by the benefit 
shown in several adult studies. Initiation of treatment with 
combination therapy has not been formally evaluated.  
Transdermal drug delivery systems have been used as safe 
and effective drug delivery devices since 1981. A lot of 
progress has been done in the field of Transdermal Patches. 
Due to large advantages of the Transdermal Drug Delivery 
System, this system interests a lot of researchers. Many new 
researches are going on in the present day to incorporate 
newer drugs via this system. Transdermal dosage forms may 
provide clinicians an opportunity to offer more therapeutic 
options to their patients to optimize their care54.  
Transdermal system for PAH treatment to the children is not 
established so far. Considering the fact of children’s 
comfortability in order to intake solid and semisolid oral or 
intravenous injection, transdermal patch with PDE inhibitors 
would be a choice of dosage form for pediatric PAH. Hence 
more research should happened to establish transdermal 
patch with PDE inhibitors for pediatric PAH. 
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